의료용 플라스틱 컴파운드 시장 보고서 : 동향, 예측 및 경쟁 분석(-2035년)

Medical Plastic Compound Market

The future of the global medical plastic compound market looks promising with opportunities in the disposable, catheter, surgical instrument, medical bag, implant, and drug delivery system markets. The global medical plastic compound market is expected to reach an estimated $51.1 billion by 2035 from $27.2 billion in 2027 with a CAGR of 7.1% from 2027 to 2035. The major drivers for this market are the increasing demand for medical devices, the rising need for patient safety, and the growing focus on healthcare advancements.

• Lucintel forecasts that, within the product category, polycarbonate is expected to witness the highest growth over the forecast period due to the rising biocompatibility for medical applications.
• Within the application category, drug delivery system is expected to witness the highest growth over the forecast period due to the increasing demand for targeted therapies.
• In terms of regions, APAC is expected to witness the highest growth over the forecast period due to the growing medical device demand.

Emerging Trends in Medical Plastic Compound Market

The medical plastic compound market is growing and moving away from the use of commodity resins to application specific formulations as medical product manufacturers require traceability, lower emissions, and a higher degree of validation. Compounders have prioritized medical grade recycled content where allowed and expect medical grade recycled content to continue to be a priority in the next few years, along with more advanced compounding and regional capacity. Lucintel expects demand for medical compounds will continue to grow due to aging populations and the increasing demand for diagnostics.

• Sustainability: Compounders expect lower carbon footprint from medical plastic compounds and expect demand for medical compounds to decrease as packaging waste regulations expected in Europe in 2026 begin to take effect. Compounder shifts will encourage lower packaging waste and will require that OEMs quantify product-related emissions.
• Digital Manufacturing: Compounders expect medical device manufacturers to connect compounding data with validated molding records. Siemens' healthcare materials for 2025 focus on digital quality control and workflows, and 21 CFR Part 11 supports electronic-record controls. Within the next few years, connected records will shorten deviations and facilitate faster change control.
• Automation: Automation of feeding and inline inspection with closed-loop dosing continues to increase in production systems. Engel Automation for Medical Injection Molding was introduced at K 2025. The standard for automation will remain ISO 13485 for medical automation. Labor scarcity and unpredictability will drive automation investment through 2030.
• Smart Materials: Compounding that includes response to light, drug-compatible, antimicrobial, and radiopaque additives will continue to grow. The FDA 2025 device guidance, along with the increasing number of connected diagnostics, will focus on higher performance and lower assay cost and time.
• Regional Supply Chain Diversification: As medical OEMs further qualify alternative sources near North America and Europe, India's medical device sector aiming for $50 billion by 2030 [cited in 2025 policy documents] indicates potential for capacity building. Dual sourcing is expected to modify the way compound specifications and qualification processes are defined in the next five years.

From 2025 to 2027, the largest opportunities for growth in the medical plastic compounds market will be based on performance qualification, as opposed to volume of resin. Sustainability claims, as well as automation and records of digital data, must stand up to audits. Suppliers that localize critical grades, perform biocompatibility testing and design for recycling, should see market growth. Even in the presence of low pricing, compliancy deeply impacts the materials that can be used in mass production.

Recent Developments in the Medical Plastic Compound Market

The medical plastic compound market is projected to show significant growth through 2025 to 2027. Drivers include regionalization of supply and demand, increased specialization of high-performance formulations, and increased compliance. Lucintel believes this growth will be primarily driven by packaging, drug delivery, diagnostics and minimally invasive devices, with tightened lead times and traceability emerging as critical factors in purchase decisions.

• BASF's March 2025 expansion of its Ludwigshafen compounding operations added 100,000 tonnes to its annual capacity for engineering plastics. This expansion is expected to improve the supply of medical-grade plastics in Europe and provide support for localized medical-grade compound production over the next three to five years.
• The completed €11.7 billion ADNOC acquisition of Covestro (December 2025) strengthens ADNOC's access to polycarbonate and polyurethane technologies. This strengthened position is expected to support the development of regional supply agreements and broaden the medical plastic compound portfolio.
• In February 2025, SABIC launched new LNP CRX copolymer medical grades, targeting drug delivery and packaging applications needing enhanced impact resistance. The use of high performance compounds leverages the expected premium pricing for drug delivery and packaging systems.
• The Packaging and Packaging Waste Regulation of the European Union (implementation begun February 2025), sets a 2030 goal of implementing recyclable packaging. Hopefully, this goal will encourage medical compounds packaging suppliers to create more compliant, recycled content packaging.
• In June 2025, Rochling Medical and an Indian manufacturing partner signed a Memorandum of Understanding, focused on supporting the needs of the growing medical device industry in India. Such collaborations serve to shorten delivery times and reduce reliance on imported raw materials.

Over the next five years, medical plastic compound suppliers will differentiate based on speed of qualification, traceability, evidence of use of recycled content, and supply assurance. Medical device clusters will create opportunities for capacity additions, while acquisitions will be used to build formulation portfolios. The ability to perform and document consistently will determine winners in the medical device sector. Medical device manufacturers will place increasing demands on their suppliers to consolidate qualified sources in each region.

Strategic Growth Opportunities in the Medical Plastic Compound Market

The medical plastic compound market is entering a new phase focused on greater value as healthcare providers look for safer, lighter, and more traceable components. Between 2024 and 2026, outsourcing of medical devices, tighter control over approved materials, and increased investment in domestic production will provide more opportunities in the marketplace. Lucintel expects suppliers of tested formulations and reliable regional supplies to capture the majority of new growth in this market.

• Biologic drugs are driving growth of biologic therapies that require components such as inhalers, autoinjectors, and infusion components. In January 2025, the FDA listed more than 170 approved biologics requiring specialized delivery formats. Over the next three to five years, formulation compatibility and low-extractables performance will favor qualified compound suppliers.
• Diagnostic devices and laboratory equipment use compounds which these devices must be optically clear, chemically resistant, and have tightly controlled dimensions. In March 2025, Roche reported more than 35,000 cobas analyzers sold worldwide. This installed base will provide ongoing requirements for customized housings, cartridges, and fluid-handling components.
• Premium antimicrobial compounds are in demand as hospitals focus on reducing contamination while maintaining the sterilization and biocompatibility of surfaces. In February 2025, the CDC reported that one in 31 hospital patients in the U.S. had at least one healthcare-associated infection. Suppliers of validated antimicrobial systems will shift from selling commodity resins to specification-based contracts.
• Medical device manufacturers are sourcing materials from multiple regions after supply chain disruptions and resin shortages showed the risks of being overly reliant on one region Manufacturing is also being moved to multiple regions. In April 2025, the European Commission allotted €1.8 billion to strengthen critical medicines production. Compounding and technical support will give suppliers the advantage in Europe, India, and Southeast Asia.
• Circular Medical Plastics: Recycled content in the area of non-invasive devices and packaging has more immediate opportunities than in the area of implants. The EU Packaging and Packaging Waste Regulation (EU PPWR) has established a goal of 30% recycled content for contact-sensitive packaging by 2030, which creates a pathway for application-specific, traced recycled compound movement within the supply chain of the healthcare sector.

The ability to provide regulatory know-how and formulation expertise will position companies in the best position for future investments. While commodity risk will still exist, the focus will likely become more regional technical support and validated grades, as well as production that is digitally monitored and controlled. Relationships with device manufacturers will carry more value than an extensive product portfolio. Companies will succeed if they design and develop materials that fulfill the requirements of the compliance framework, including design for sterilization and end of life.

Medical Plastic Compound Market Drivers and Challenges

The medical plastic compound market is affected by emerging technologies, changing demand for healthcare, economic conditions, sustainability concerns, and new regulations. As revealed by Lucintel, more innovative materials and advanced processing are essential, because manufacturers need safe, lightweight, recyclable, and cost-effective solutions. Current trends in the marketplace also include supply chain risks, changing regulations, and pricing pressures.

Factors that will positively affect the medical plastic compound market are:

• Increasing Demand for Healthcare Services: The aging population and the growth of health services and the use of more and more disposable medical devices, create the demand for a greater use of medical plastic compounds. The World Health Organization has predicted that by 2050, the world population over the age of 60 will have grown to 2.1 billion. More syringes, diagnostics, implants, medical packaging, and delivery systems will be used. During the next three to five years, high demand for these medical products will be created as hospitals focus on infection control, there is growth in health care at home, and developing countries build their medical infrastructures. Suppliers of compounds who develop sterilization-resistant, biocompatible, and application-specific compounds will hold the strongest market positions.
• Technological Material Innovation: Recent advancements in polymer chemistry and compounding, additive manufacturing, and surface modification enable medical plastics to possess strengths, flexibility, resistance to chemicals, and improve their performance after sterilization. The Food and Drug Administration, USA, published in March 2025, more than 10,000 listed medical-device manufacturing facilities, showing the extent of the diverse materials required for different applications. New compounds integrate the integration of antimicrobial, radiopaque, conductive, and low-friction properties into lightweight structures. Over the next three to five years, we can expect more advanced devices that will incorporate small, sophisticated, and more user-centric medical equipment, along with the replacement of metals, glass, and conventional polymers.
• Sustainability and Recyclability: The need for sustainable solutions drives material reduction, development of bio-based alternatives, and medical safety improved recyclability. In February 2025, the European Union implemented the framework of its packaging waste, targeting a 15 % reduction of packaging waste produced per person by 2040, compared to 2018. While strict safety standards on medical devices slow the use of different designs, manufacturers are developing mono-material designs, using recycled materials, and improving the sustainability of production. Over the next three to five years, the focus will be on the sustainability of production and supply in order to secure the supply of medical devices, approval of production, and the maintenance of market reputation and long-term contracts with suppliers.
• Manufacturing Efficiency and Cost Advantages: Innovations like advanced compounding, automation, digital quality control, and the use of lightweight design help manufacturers produce devices that waste less, are used more consistently, and decrease their total cost. The International Federation of Robotics reported that global industrial robot installations surpassed 500,000 units each year between 2020 and 2025. One benefit to medical device manufacturers of using plastics compared to using metals is plastics have more design flexibility, require less transportation, and have reduced weight during high-volume molding. There will be more opportunities to use plastic in healthcare over the next 3 to 5 years. This is due to increasing demands for greater efficiency and quality while labor gets more expensive and in short supply.
• Product Innovation and Device Miniaturization: The fast-growing markets for connected and smart devices, diagnostics, and drug delivery systems lead to even higher demand for specialized functional properties and dimensional stability in materials. In 2025, the International Diabetes Federation estimated that 589 million adults around the world had diabetes, increasing demand for monitoring and delivery systems. Plastics allow for design that is compact, lightweight, and easy to use. In the next 3 to 5 years, product design will focus on materials that integrate multiple functions and offer high stability in sterilization processes.

This market faces the following challenges:

• Challenges Related To Compounding Medical Plastics: Compounding medical plastics is a complex process with a number of demanding specifications relating to the biocompatibility of compounds and the limits of extractables and leachables, sterilization, traceability and performance longevity. In January 2025, the Medical Device Regulation of the European Union continued to apply comprehensive conformity to medical devices from different categories along the value chain, placing greater demands on documentation and validation. Smaller compounders are disproportionately affected by increased longevity of the developmental process and increased costs of testing. In the next three to five years, regulatory requirements will expand beyond the scope of the current requirements to encompass safety of chemicals, use of recycled materials in products, and greater transparency of supply chains. Companies with weak compliance systems are likely to experience prolonged approval processes, product formulations changes, and/or loss of preferred supplier status.
• Challenges Related To Compounding Medical Plastics: With the compounding of medical plastics, exponentially increasing energy costs, geopolitical tensions, supply chain instability, and insufficient supply from a concentration of suppliers have resulted in major supply chain disruptions and price volatility. In February 2025, the International Monetary Fund reported geopolitical fragmentation will continue to impact global trade and supply chains. Volatile pricing will stretch margins and disrupt production. In the next three to five years, it will be necessary for firms to implement regional sourcing, use of dual-qualified suppliers, supplier inventory, and strategies of alternate-material substitution to protect the integrity of validated product specifications.
• Recycling and Sterilization Limitations: Many healthcare items get recycled, but they are easily contaminated, have multilayer construction, or are made from materials requiring traceability. In June 2025, the World Health Organization continued reporting that medical waste makes up about 15% of total waste generated from medical work and can be dangerous. There may also be issues about the uniformity and purity of the recycled materials, as well as sterilization and regulatory approval. Limited collection systems and conservative clinical needs will be problems for the adoption of recycled materials for at least three to five years in the future. During this time, most healthcare organizations will be obligated to invest in controlled recovery systems and circular economy material designs.

Increasing demand for healthcare, advances in materials, increasing automation, and downsizing of medical technologies, will create a growing opportunity for medical plastics. However, strict approvals, unpredictable costs, supply shortages and challenges with recycling will create roadblocks and increase the cost of market entry for competitors. Manufacturers that can produce validated high-performance compounds in a reliable supply network, combined with efficient processing and eco-friendly designs, will have a competitive advantage over other manufacturers. For the next three to five years, the market is expected to be steady, but favor select suppliers that have a combination of regulations, technical expertise, low cost, and measurable sustainability.

List of Medical Plastic Compound Market Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies medical plastic compound market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the medical plastic compound market companies profiled in this report include-

• BASF
• Dow
• DuPont
• Eastman Chemical Company
• Evonik Industries
• SABIC
• Celanese Corporation
• Tekni-Plex
• RAUMEDIC
• Solvay

Medical Plastic Compound Market by Segment

The study includes a forecast for the global medical plastic compound market by product, application, and region.

Medical Plastic Compound Market by Product [Value ($B) from 2019 to 2035]:

• Polyvinylchloride
• Polyethylene
• Polypropylene
• Polystyrene
• Polyester
• Polycarbonate
• Polyurethane
• Acrylics
• Others

Medical Plastic Compound Market by Application [Value ($B) from 2019 to 2035]:

• Disposables
• Catheters
• Surgical Instruments
• Medical Bags
• Implants
• Drug Delivery System
• Others

Medical Plastic Compound Market by Region [Value ($B) from 2019 to 2035]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Medical Plastic Compound Market

The medical plastic compound market will experience changes over the next few years due to more stringent quality requirements for devices, regional supply chains, and higher demand for performance polymers. Lucintel expects structural shifts in the market will affect supplier priorities; however, outcomes will ultimately hinge on regulatory frameworks and whether customers qualify suppliers.

• United States: The United States Food and Drug Administration (FDA) Quality Management System Regulation is set to implement in February 2026. The regulation will further align the manufacturing of medical devices with ISO 13485. Meanwhile, Avient continues to increase the healthcare-grade compounding and formulations in the North American region. With the regulation, customers will start to expect supply of validation and traceability documentation, change control, and continuous stability.
• China: The 2025 Chinese Government Work Program continues to support the manufacturing of high-end medical equipment and advanced materials, while Covestro's operations in Shanghai provide mid and low-volume supply of medical grade polycarbonates and related specialty polymers. According to NMPA-linked industry reports, in 2023 the medical devices market reached over RMB1 trillion in China. Government initiatives for local manufacturing and domestic qualification will provide market opportunities for compounders to manufacture and convene critical medical polymers.
• Germany: Germany continues to be a leading medical device manufacturing base in Europe as the EU Medical Device Regulation goes into effect for all new product registrations. BASF's Ludwigshafen site, Europe's largest integrated chemical complex, manufactures engineered polymers used in healthcare applications. The regulatory environment will favor compound suppliers with stable production capabilities, strong technical files, and performance biocompatibility in Europe.
• India: Coverage of medical device Production Linked Incentive (PLI) Scheme has approved ₹3,420 crore and focuses on four medical device product categories. Companies such as Poly Medicure and Meril Life Science have adopted domestic manufacturing. The long-term effect of these investments is likely to create significant value in local consumption of medical-grade compounds, creating less reliance on imported final component and specialized formulations.
• Japan: The Ministry of Health, Labour and Welfare, Japan, has reported production of medical devices for the year 2023, valued at approximately $39 billion. Domestic chemical manufacturers have begun sourcing advanced grades of sterilization-resistant and biocompatible materials. New partnerships with advanced material suppliers are expected to support the aging-care equipment market and provide a stable demand of high-reliability compounds over the next 3-5 years.

Features of the Global Medical Plastic Compound Market

• Market Size Estimates: medical plastic compound market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions.
• Segmentation Analysis: medical plastic compound market size by product, application, and region in terms of value ($B).
• Regional Analysis: medical plastic compound market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different product, application, and regions for the medical plastic compound market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the medical plastic compound market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the medical plastic compound market by product (polyvinylchloride, polyethylene, polypropylene, polystyrene, polyester, polycarbonate, polyurethane, acrylics, and others), application (disposables, catheters, surgical instruments, medical bags, implants, drug delivery system, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 6 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

• 2.1 Background and Classifications
• 2.2 Supply Chain

3. Market Trends & Forecast Analysis

• 3.2 Industry Drivers and Challenges
• 3.3 PESTLE Analysis
• 3.4 Patent Analysis
• 3.5 Regulatory Environment

4. Global Medical Plastic Compound Market by Product

• 4.1 Overview
• 4.2 Attractiveness Analysis by Product
• 4.3 Polyvinylchloride: Trends and Forecast (2019-2035)
• 4.4 Polyethylene: Trends and Forecast (2019-2035)
• 4.5 Polypropylene: Trends and Forecast (2019-2035)
• 4.6 Polystyrene: Trends and Forecast (2019-2035)
• 4.7 Polyester: Trends and Forecast (2019-2035)
• 4.8 Polycarbonate: Trends and Forecast (2019-2035)
• 4.9 Polyurethane: Trends and Forecast (2019-2035)
• 4.10 Acrylics: Trends and Forecast (2019-2035)
• 4.11 Others: Trends and Forecast (2019-2035)

5. Global Medical Plastic Compound Market by Application

• 5.1 Overview
• 5.2 Attractiveness Analysis by Application
• 5.3 Disposables: Trends and Forecast (2019-2035)
• 5.4 Catheters: Trends and Forecast (2019-2035)
• 5.5 Surgical Instruments: Trends and Forecast (2019-2035)
• 5.6 Medical Bags: Trends and Forecast (2019-2035)
• 5.7 Implants: Trends and Forecast (2019-2035)
• 5.8 Drug Delivery System: Trends and Forecast (2019-2035)
• 5.9 Others: Trends and Forecast (2019-2035)

6. Regional Analysis

• 6.1 Overview
• 6.2 Global Medical Plastic Compound Market by Region

7. North American Medical Plastic Compound Market

• 7.1 Overview
• 7.2 North American Medical Plastic Compound Market by Product
• 7.3 North American Medical Plastic Compound Market by Application
• 7.4 United States Medical Plastic Compound Market
• 7.5 Mexican Medical Plastic Compound Market
• 7.6 Canadian Medical Plastic Compound Market

8. European Medical Plastic Compound Market

• 8.1 Overview
• 8.2 European Medical Plastic Compound Market by Product
• 8.3 European Medical Plastic Compound Market by Application
• 8.4 German Medical Plastic Compound Market
• 8.5 French Medical Plastic Compound Market
• 8.6 Spanish Medical Plastic Compound Market
• 8.7 Italian Medical Plastic Compound Market
• 8.8 United Kingdom Medical Plastic Compound Market

9. APAC Medical Plastic Compound Market

• 9.1 Overview
• 9.2 APAC Medical Plastic Compound Market by Product
• 9.3 APAC Medical Plastic Compound Market by Application
• 9.4 Japanese Medical Plastic Compound Market
• 9.5 Indian Medical Plastic Compound Market
• 9.6 Chinese Medical Plastic Compound Market
• 9.7 South Korean Medical Plastic Compound Market
• 9.8 Indonesian Medical Plastic Compound Market

10. ROW Medical Plastic Compound Market

• 10.1 Overview
• 10.2 ROW Medical Plastic Compound Market by Product
• 10.3 ROW Medical Plastic Compound Market by Application
• 10.4 Middle Eastern Medical Plastic Compound Market
• 10.5 South American Medical Plastic Compound Market
• 10.6 African Medical Plastic Compound Market

11. Competitor Analysis

• 11.1 Product Portfolio Analysis
• 11.2 Operational Integration
• 11.3 Porter's Five Forces Analysis
  • Competitive Rivalry
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Threat of New Entrants
• 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

• 12.1 Value Chain Analysis
• 12.2 Growth Opportunity Analysis
  • 12.2.1 Growth Opportunities by Product
  • 12.2.2 Growth Opportunities by Application
• 12.3 Emerging Trends in the Global Medical Plastic Compound Market
• 12.4 Strategic Analysis
  • 12.4.1 New Product Development
  • 12.4.2 Certification and Licensing
  • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

• 13.1 Competitive Analysis
• 13.2 BASF
  • Company Overview
  • Medical Plastic Compound Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.3 Dow
  • Company Overview
  • Medical Plastic Compound Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.4 DuPont
  • Company Overview
  • Medical Plastic Compound Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.5 Eastman Chemical Company
  • Company Overview
  • Medical Plastic Compound Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.6 Evonik Industries
  • Company Overview
  • Medical Plastic Compound Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.7 SABIC
  • Company Overview
  • Medical Plastic Compound Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.8 Celanese Corporation
  • Company Overview
  • Medical Plastic Compound Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.9 Tekni-Plex
  • Company Overview
  • Medical Plastic Compound Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.10 RAUMEDIC
  • Company Overview
  • Medical Plastic Compound Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 13.11 Solvay
  • Company Overview
  • Medical Plastic Compound Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing

14. Appendix

• 14.1 List of Figures
• 14.2 List of Tables
• 14.3 Research Methodology
• 14.4 Disclaimer
• 14.5 Copyright
• 14.6 Abbreviations and Technical Units
• 14.7 About Us
• 14.8 Contact Us